Commentator views former Ørsted CEO as potential Novo Nordisk chairman

For life science companies, it's no longer enough to have experts from own industry in the board room, according to business commentator Jens Christian Hansen. He sees many advantages to Novo Nordisk's interest in including former Ørsted CEO Henrik Poulsen in the company board.

If a life science company includes people from outside the industry in its board, it can turn into a huge advantage – even if they don't have expert knowledge on the industry, according to business commentator Jens Christian Hansen.

He sees a clear tendency in Tuesday's announcements that Novo Nordisk has nominated Danish utility Ørsted's former President & CEO Henrik Poulsen for its company board at the same as Google's Country Director for Denmark, Malou Aamund, enters WS Audiology's board.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs